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The worldwide prevalence of extended-spectrum-beta-lactamase-producing ESBL-producing Enterobacteri-
aceae (ESBL-E) is increasing, making the need for optimized detection techniques more urgent. In this study
we investigated the performance of two ESBL-E screening and two ESBL-E confirmation techniques. In
accordance with the Dutch national guidelines (www.wip.nl), a collection of 642 highly resistant Enterobac-
teriaceae strains, as identified by Vitek2, was used to test the performances of two screening techniques (EbSA
ESBL agar plate and ChromID ESBL agar plate) and of two confirmation techniques (MIC-strip ESBL and
Vitek2 ESBL test panel). The individual test results were compared by using Etest, followed by a combination
disk test if Etest results were inconclusive. Among group 1 isolates (Escherichia coli, Klebsiella spp., Proteus spp.,
Salmonella spp., and Shigella spp.) 291 (57.6%) were ESBL-E, versus 65 (47.4%) in group 2 (Enterobacter spp.,
Citrobacter spp., Morganella morganii, Serratia spp., and Providencia spp.). The sensitivities of all four tests for
group 1 were comparable (EbSA, 96.6%; ChromID, 97.3%; MIC-strip, 99.6%; and Vitek2, 95.1%). The speci-
ficities of the EbSA and ChromID were the same (93.9%). However, the confirmation techniques produced
many inconclusive test results, which reduces the applicability in routine laboratories. Only the two screening
agar plates were validated for ESBL testing of group 2 microorganisms. They showed comparable sensitivities;
however, the EbSA screening agar plate had a significantly higher specificity (78.6% versus 44.3%). In
conclusion the screening agar plates performed better than the two confirmation techniques. The EbSA agar
plate had the best overall performance.
The worldwide prevalence of extended-spectrum-beta-lacta-
mase-producing Enterobacteriaceae (ESBL-E) is increasing
rapidly (3, 4). In the annual report of 2008, the European
Antimicrobial Resistance Surveillance System (EARSS), avail-
able at the RIVM website (http://www.rivm.nl/earss/result
/Monitoring_reports/), concluded that resistance of E. coli to
extended-spectrum cephalosporins has increased significantly
since 2001 in nearly all European countries.
Infections caused by ESBL-E are associated with an increase
of morbidity, mortality, and health care costs (8, 9). To ensure
patient safety, optimal treatment and control of the spread of
ESBL-E are essential. Isolation of colonized patients is one of
the most important control measures (7) and should be insti-
tuted as soon as possible. This requires accurate and rapid
laboratory diagnosis.
Different screening and confirmatory techniques have been
described in the literature. The objective of this study was to
compare two screening agar plates and two confirmatory tech-
niques to detect ESBL-E among a collection of clinically rel-
evant strains. For this we used a well-defined collection of
highly resistant microorganisms from a recent study in Dutch
hospitals.
MATERIALS AND METHODS
Strain collection. The strains were part of a collection from a multicenter study
containing 892 highly resistant Gram-negative rods. The strains were collected in
five university hospitals, eight teaching hospitals, and five general hospitals dur-
ing a 6-month study period in 2007. The strains were recovered from clinical
cultures and screening cultures. The screening samples were predominantly
nasal, throat, and rectal swabs (11). In total, 642 highly resistant Enterobacteri-
aceae (HRE) isolates were included in this analysis. If two isolates from one
patient were included, the strains were unique regarding the species identifica-
tion or resistance pattern. The criteria used for definition of HRE are described
in the Dutch national guidelines for the control of highly resistant microorgan-
isms (7). Table 1 shows a summary of these criteria.
Reference method. The strains were identified as HRE by the local microbi-
ology laboratories and sent to a central laboratory. In the central laboratory,
identification and susceptibility testing of the strains were confirmed using the
Vitek2 system (bioMe´rieux, Marcy l’Etoile, France) with “GN” and “AST-N020”
cards. The isolates were divided into group 1 (Escherichia coli, Klebsiella spp.,
Proteus mirabilis, Salmonella spp., and Shigella spp.) and group 2 (Enterobacter
spp., Serratia spp., Providencia spp., Citrobacter freundii, Morganella morganii, and
Hafnia alvei) microorganisms according to the Dutch guidelines for ESBL de-
tection (1). This division is based on the presence of chromosomal AmpC
beta-lactamase in the species of group 2 and the resulting decreased sensitivity to
ceftazidime or cefotaxime. Confirmation of the presence of ESBL was performed
by using Etest (bioMe´rieux, Marcy l’Etoile, France) on all isolates. If the Etest
was inconclusive, a combination disc diffusion test (Rosco, Taastrup, Denmark)
was performed to confirm the presence of ESBL. Group 1 microorganisms were
tested for synergy between ceftazidime and clavulanic acid and between cefo-
taxime and clavulanic acid. Group 2 microorganisms were tested for synergy
between cefepime and clavulanic acid. Group 1 microorganisms that were ce-
foxitin resistant were also tested for synergy between cefepime and clavulanic
acid. This procedure was considered the gold standard.
EbSA ESBL screening agar plate. The EbSA ESBL screening agar plate
consists of a double MacConkey agar plate containing ceftazidime (1.0 mg/liter)
on one side and cefotaxime (1.0 mg/liter) on the other side. (AlphaOmega,
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’s-Gravenhage, Netherlands). Both sides contain cloxacillin (400 mg/liter) and
vancomycin (64 mg/liter) for inhibition of AmpC beta-lactamase-producing bac-
teria and Gram-positive bacteria, respectively. Both sides of the screening agar
were inoculated with 1 l (a standard loopful) of a 0.5 McFarland standard
suspension of Enterobacteriaceae. Subsequently they were incubated aerobically
at 35 to 37°C for 18 to 24 h in an inverted position. Growth on either side of the
agar plate was interpreted as a positive screening result.
ChromID ESBL screening agar plate. The ChromID ESBL screening agar
plate contains a mixture of antibiotics, including cefpodoxim, two chromogenic
substrates, and one natural substrate, to enable direct species identification
(bioMe´rieux, Marcy l’Etoile, France). The species identification was not part of
our evaluation. The screening agar plate was inoculated with 1 l (a standard
loopful) of a 0.5 McFarland standard suspension of Enterobacteriaceae. Subse-
quently, the agar was incubated aerobically at 35 to 37°C for 18 to 24 h in an
inverted position. Growth on the agar was considered a positive test result.
MIC-strip ESBL. The MIC-strip ESBL is a broth microdilution assay (Bio-
Trading, Mijdrecht, Netherlands) which is validated only for group 1 microor-
ganisms. Therefore, group 2 microorganisms were excluded for this analysis. The
test consists of 11 wells containing different amounts of antibiotic; 6 wells con-
tained cefpodoxim, 4 wells contained cefpodoxim plus clavulanic acid, and 1
control well contained no antibiotics. Mueller-Hinton broth was inoculated with
a 0.5 McFarland standard bacterial suspension, resulting in a 1:200 dilution. Of
this dilution, 100 l was inoculated in each well of the MIC-strip. Subsequently,
the MIC-strip was incubated aerobically at 35 to 37°C for 18 to 24 h, and then a
visual check for growth was executed, based on turbidity. The lowest concentra-
tion with no detectable growth was considered the MIC. A MIC reduction of
three or more dilution steps was considered indicative of ESBL production.
Vitek2 ESBL test panel. The AST-EXN4 card (bioMe´rieux, Marcy l’Etoile,
France) was used in combination with the Vitek2 system. The panel has six wells
containing 1.0 g/ml cefepime, 0.5 g/ml cefotaxime, or 0.5 g/ml ceftazidime
alone and in combination with clavulanic acid (10 g/ml, 4 g/ml, or 4 g/ml,
respectively). Growth in the wells was quantitatively assessed by means of an
optical scanner. The proportional reduction in growth in wells containing a
cephalosporin with clavulanic acid compared with those containing the cepha-
losporin without clavulanic acid was considered indicative of ESBL production.
This test is validated only for group 1 microorganisms, and therefore group 2
microorganisms were excluded from the analysis.
Statistical analysis. All screening tests were compared to the reference
method, the ESBL Etest, combined when needed with the combination disk
diffusion as described above. The sensitivities and specificities of the tests were
determined; the analysis was done separately for group 1 and group 2 microor-
ganisms. Differences in sensitivity and specificity between the two groups were
analyzed with the chi-square test or Fisher’s exact test when appropriate. Statis-
tical significance was accepted when the chance for coincidence was less than 5%.
All analysis were performed using the Statistical Package for Social Sciences
software (SPSS version 17).
RESULTS
There were a total of 642 highly resistant Enterobacteriaceae
strains, of which 505 (78.7%) were classified as group 1 and 137
(21.3%) as group 2. The distribution of the various species of
microorganisms is shown in Table 2. E. coli was the most
frequently encountered species in group 1, and Enterobacter
spp. were most frequently encountered in group 2. According
to the reference method, a total of 356 isolates (55.5%) were
confirmed as ESBL producers. Of the ESBL-positive isolates,
291 (81.7%) belonged to group 1 and 65 (18.3%) belonged to
group 2. There were two Enterobacter spp. for which the ESBL
status could not be determined. These two isolates were ex-
cluded from the evaluation of the screening agar plates and the
confirmatory methods.
Group 1 microorganisms. The results of the different tests
for the group 1 microorganisms are shown in Table 3. Of 505
group 1 microorganisms, 294 (58.2%) were suspected ESBL
producers as determined using the EbSA screening agar. Thir-
teen isolates were false positives and 12 false negatives. The
calculated sensitivity was 96.6%, and the specificity was 93.9%.
Using the ChromID screening agar, 296 (58.6%) isolates were
suspected ESBL producers. Thirteen isolates were false posi-
tives, and eight were false negatives. The sensitivity and spec-
ificity of this test method were 97.3% and 93.9%, respectively.
Using the MIC-strip, 285 (56.4%) isolates were suspected
ESBL producers. Ten isolates were false positives, and one was
a false negative. The results for 117 isolates (23.2%) were not
interpretable. The results for the noninterpretable isolates
were excluded for sensitivity and specificity calculations. The
calculated sensitivity was 99.6%, and the specificity was 91.1%.
Using the Vitek2 test panel, 291 isolates (57.6%) were sus-
pected ESBL producers. Twenty isolates were false positives,
and 14 were false negatives. The Vitek2 system did not provide
results for 52 isolates (10.3%), mainly due to lack of validation
of the bacterial species involved. Some missing results were
due to test inconsistencies. These isolates were not included in
the sensitivity and specificity calculations. The resulting sensi-
tivity of this test method was 95.1%, and the specificity was
88.1%.
Because of the high proportion of invalid test results with
both the MIC-strip and the Vitek2 test panel, we did not
perform a statistical comparison of these tests with the two
screening agar plates. A comparison of the performances of
the two screening agar plates showed that the screening agar
plates were comparable in regard to sensitivity (P 0.812) and
specificity (P  1.000).
Group 2 microorganisms. The results of the different tests
for the group 2 microorganisms are shown in table 4. Of 137
TABLE 1. Definition of highly resistant Enterobacteriaceae
Species
Definition of resistancea
ESBL CAR QUI AMG COT
Escherichia coli A A B B
Klebsiella spp. A A B B
Other A A B B B
a ESBL, extended-spectrum beta-lactamases; CAR, carbapenems; QUI, fluo-
roquinolones; AMG, aminoglycosides; COT, co-trimoxazole. A, resistance
against an antibacterial agent of the carbapenem group and/or presence of ESBL
production is sufficient to define the microorganism as highly resistant; B, resis-
tance against antibacterial agents from at least two of the indicated groups or
specified antibacterial agents is required to define the microorganism as highly
resistant.
TABLE 2. Strain collection
Group and species
n (%) of isolates as determined by reference method
ESBL
positive
ESBL
negative Inconclusive Total
1
Total 291 (57.6) 214 (42.4) 0 (0.0) 505 (78.7)
Escherichia coli 190 (56.9) 144 (43.1) 0 (0.0) 334 (66.1)
Klebsiella spp. 98 (79.0) 26 (21.0) 0 (0.0) 124 (24.6)
Proteus spp. 2 (4.8) 40 (95.2) 0 (0.0) 42 (8.3)
Salmonella spp. 1 (33.3) 2 (66.7) 0 (0.0) 3 (0.6)
Shigella spp. 0 (0.0) 2 (100.0) 0 (0.0) 2 (0.4)
2
Total 65 (47.4) 70 (51.1) 2 (1.5) 137 (21.3)
Enterobacter spp. 58 (64.4) 30 (33.3) 2 (2.2) 90 (65.7)
Citrobacter spp. 7 (23.3) 23 (76.7) 0 (0.0) 30 (21.9)
Morganella morganii 0 (0.0) 9 (100.0) 0 (0.0) 9 (6.6)
Serratia marcescens 0 (0.0) 6 (100.0) 0 (0.0) 6 (4.4)
Providencia spp. 0 (0.0) 2 (100.0) 0 (0.0) 2 (1.5)
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microorganisms, 80 (58.4%) were suspected ESBL producers
as determined using the EbSA screening agar plate. Fifteen
isolates were false positives, and two were false negatives. The
sensitivity was 96.9%, and the specificity was 78.6%. Using the
ChromID screening agar plate, 105 isolates (76.6%) were sus-
pected ESBL producers. Thirty-nine isolates were false posi-
tives and one was a false negative, resulting in a sensitivity of
98.5% and a specificity of 44.3%. For group 2 microorganisms,
the sensitivities of the two tests were comparable, but the
specificity was significantly higher for the EbSA screening agar
plate (P  0.001).
DISCUSSION
In this study we evaluated the performances of two ESBL
screening agar plates and two ESBL confirmatory tests. Our
evaluation showed that the two ESBL-E screening agar plates
had good sensitivity for group 1 microorganisms (96.5%).
The two confirmation tests (MIC-strip and Vitek2 ESBL
panel) also showed good sensitivity for the group 1 microor-
ganisms; however, both tests had a large number of invalid test
results, which limits their applicability in routine use. The spec-
ificities of the two screening agar plates were identical and high
(93.9%). The two confirmatory tests also showed good and
comparable specificities. However, as stated above, the large
number of invalid test results reduces the applicability of these
two tests. If these invalid test results were included in our
calculation and classified as false-positive results, the specificity
would be significantly lower than the specificity for the two
screening agar plates.
For group 2 microorganisms, the sensitivities of the two
screening agar plates were comparable and high (96.5%).
However, the specificity of the EbSA was significantly higher
than the specificity of the ChromID (P  0.001). The differ-
ence in specificity for group 2 microorganisms makes the EbSA
the most reliable test in this evaluation.
Both confirmation techniques were not validated for group 2
microorganisms. This further reduces the applicability of these
tests in daily practice. Moreover, our comparison showed that
the specificities of these tests were significantly lower than the
specificities of the screening agar plates. This is remarkable, as
confirmation techniques should have a higher specificity then
screening tests. Therefore, the screenings agar plates are more
suited as confirmatory tests than the two “confirmatory tests”
that were included in this analysis.
There are few other evaluations of the screening agar plates
that we used. Al Naiemi et al. (2) evaluated the EbSA screen-
ing agar plate with a collection of 208 Enterobacteriaceae
strains. The ESBL status of the isolates was determined by
genotyping; 70 isolates were found to be positive. They found
an overall sensitivity of 100% and a specificity of 84.7%. The
sensitivity and specificity that we calculated were comparable
with these results (P  0.114 and P  0.107, respectively).
Huang et al. (6) evaluated the ChromID with a collection of
156 Enterobacteriaceae strains. Eight fully susceptible isolates
were inhibited, and all 98 ESBL producers were detected. Fifty
isolates harboring other resistance mechanisms were also re-
covered. These results are comparable to our data, considering
the fact that they did not divide the Enterobacteriaceae into two
groups.
To our best knowledge, an evaluation of the MIC-strip and
Vitek2 ESBL test panel (AST-EXN4) confirmation techniques
has not been described before.
Our study has a few limitations. First, we used a phenotypic
reference method. Using a genotypic reference method could
affect the results. Cohen Stuart et al. (5) recently evaluated an
ESBL microarray and compared it with the ESBL Etest
method that we used. They found limited numbers of false-
positive (2/106) and false-negative (2/212) ESBL Etest results
compared with sequencing. Consequently, if we had used a
genotypic method, the sensitivities and specificities obtained
could have been slightly different. Second, in daily practice the
screening agar plates will be inoculated directly with patient
materials, because they are produced to use as screening tech-
niques. This could theoretically affect the growth of bacteria on
these media; however, a recent study (6) showed a sensitivity
and specificity of 94.9% in a collection of 528 clinical samples
with the ChromID screening agar plate.
Our evaluation shows that both media can detect ESBL-
producing Enterobacteriaceae reliably. The ChromID has a
TABLE 3. Results of different screening tests for group 1 microorganisms
NVMM
guideline
No. of isolates with indicated ESBL test result
EbSA ChromID MIC strip Vitek2 test panel
Positive Negative Positive Negative Positive Negative Inconclusivea Positive Negative Inconclusivea
ESBL positive 281 10 283 8 275 1 15 271 14 6
ESBL negative 13 201 13 201 10 102 102 20 148 46
Sensitivity (%) 96.6 97.3 99.6 95.1
Specificity (%) 93.9 93.9 91.1 88.1
a Inconclusive test results were excluded from sensitivity and specificity calculations.
TABLE 4. Results of different screening tests with
group 2 microorganisms
NVMM
guideline
No. of isolates with indicated ESBL test result
EbSA ChromID
Positive Negative Positive Negative
ESBL positive 63 2 64 1
ESBL negative 15 55 39 31
Sensitivity (%) 96.9 98.5
Specificity (%) 78.6 44.3
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lower specificity and will therefore require more confirmatory
testing, increasing the total laboratory costs and turnaround
times for the results.
A recent study by Tumbarello et all. (10) reported that
ESBL infections in the bloodstream were associated with
longer (7 days) and costlier (mean additional costs, €5026.00)
hospital stays and increased 21-day mortality (29,7% versus
6.1%). These findings indicate the need to use reliable and fast
detection tests for ESBL. Use of the EbSA in daily practice will
help to shorten the period of inadequate therapy, which is
related to a higher mortality.
In conclusion, in our study the EbSA screening agar plate
was the best screening test to use. The ChromID also per-
formed adequately, but it had a lower specificity, which in-
creases the laboratory cost and turnaround time.
ACKNOWLEDGMENTS
We are indebted to all members of the TRIANGLe study group: E.
Lommerse and L. Spanjaard, Academic Medical Centre, Amsterdam,
Netherlands; B. Vlaminckx, Antonius Hospital, Nieuwegein, Nether-
lands; A. Vos, Canisius Wilhelmina Hospital, Nijmegen, Netherlands;
M. Wulf, Catharina Hospital, Eindhoven, Netherlands; M. Vos, Eras-
mus University Medical Center, Rotterdam, Netherlands; R. Winter-
mans, Fransiscus Hospital, Roosendaal, Netherlands; G. Andriesse,
Lievensberg Hospital, Bergen op Zoom, Netherlands; J. van Zeijl,
Medical Center Leeuwarden, Leeuwarden, Netherlands; E. van der
Vorm, Reinier de Graaf Groep, Delft, Netherlands; A. Buiting, Sint
Elisabeth Hospital, Tilburg, Netherlands; P. Sturm, University Medical
Center Nijmegen, Nijmegen, Netherlands; H. Blok and A. Troelstra,
Department of Medical Microbiology and Infectious Diseases, Uni-
versity Medical Center, Amsterdam, Netherlands; and A. Kaiser and
C. Vandenbroucke-Grauls, VUmc University Medical Center, Am-
sterdam, Netherlands.
bioMe´rieux, Marcy l’Etoile, France, supported the study by provid-
ing the ChromID agar plates and the Vitek2 AST-EXN4 cards. Bio-
Trading, Mijdrecht, Netherlands, supported the study by providing the
MIC strips. AlphaOmega, ’s-Gravenhage, Netherlands, supported the
study by providing the EbSA ESBL agar plates.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
REFERENCES
1. al Naiemi, N., J. Cohen Stuart, and M. Leverstein van Hall. 2008. NVMM
guidelines for screening and confirmation of extended-spectrum-beta-lacta-
mases (ESBL’s) in Enterobacteriaceae. http://www.nvmm.nl/richtlijnen/esbl
-screening-en-confirmatie.
2. Al Naiemi, N., J. L. Murk, P. H. M. Savelkoul, C. M. J. Vanderbroucke-
Grauls, and Y. J. Debets-Ossenkopp. 2009. Extended-spectrum beta-lacta-
mases screening agar with AmpC inhibition. Eur. J. Clin. Microbiol. Infect.
Dis. 28:989–990.
3. Bush, K. 2008. Extended-spectrum beta-lactamases in North America, 1987–
2006. Clin. Microbiol. Infect. 14(Suppl. 1):134–143.
4. Canton, R., et al. 2008. Prevalence and spread of extended-spectrum beta-
lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect.
14(Suppl. 1):144–153.
5. Cohen Stuart, J., et al. 2010. Rapid detection of TEM, SHV and CTX-M
extended spectrum beta-lactamases in Enterobacteriaceae using ligation me-
diated amplification with micro-array analysis. J. Antimicrob. Chemother.
65:1377–1381.
6. Huang, T. D., P. Bogaerts, C. Berhin, A. Guisset, and Y. Glupczynski. 2010.
Evaluation of Brilliance ESBL agar, a novel chromogenic medium for de-
tection of extended-spectrum-beta-lactamase-producing Enterobacteriaceae.
J. Clin. Microbiol. 48:2091–2096.
7. Kluytmans-Vandenberg, M. F. Q., J. A. J. W. Kluytmans, and A. Vos. 2005.
Dutch guideline for preventing nosocomial transmission of highly resistant
micro-organisms (HRMO). Infection 33:309–313.
8. Roberts, R. R., et al. 2009. Hospital and societal costs of antimicrobial-
resistant infections in a Chicago teaching hospital: implications for antibiotic
stewardship. Clin. Infect. Dis. 49:1175–1184.
9. Schwaber, M. J., and Y. Carmeli. 2007. Mortality and delay in effective
therapy associated with extended-spectrum -lactamase production in En-
terobacteriaceae bacteraemia: a systemic review and meta-analysis. J. Anti-
microb. Chemother. 60:913–920.
10. Tumbarello, M., et al. 2010. Costs of bloodstream infections caused by
Escherichia coli and influence of extended-spectrum -lactamase production
and inadequate initial antibiotic therapy. Antimicrob. Agents Chemother.
54:4085–4091.
11. Willemsen, I., et al. Highly resistant Gram-negative micro-organisms: inci-
dence density and occurrence of noscomial transmission (TRIANGLe
study). Infect. Control Hosp. Epidemiol., in press.
522 OVERDEVEST ET AL. J. CLIN. MICROBIOL.
 o
n
 M
arch 10, 2012 by VRIJE UNIVERSITEIT
http://jcm.asm.org/
D
ow
nloaded from
 
